R&D News

Ensol Biosciences Expands Licensing Agreement for Degenerative Disc Disease Treatment P2K

Ensol Bioscience2024-10-01

Pharma Research Secures $160 Million Investment from CVC to Expand Globally

Pharma Research has secured a $160 million investment through redeemable convertible preference shares (RCPS) issuance from European global private equity firm CVC, establishing a vital platform for global market expansion. This strategic partnership with CVC, a leading European fund managing approximately $230 billion, will accelerate Pharma Research's entry into international markets. CVC's investment represents a significant endorsement of Pharma Research’s potential, as the firm has a suc...

PharmaResearch2024-10-01

Y-Biologics Signs $1.3 Billion Licensing Agreement for IMB-101 with U.S. Navigator Medicine

YBIOLOGICS2024-10-01

Xcell Therapeutics Presents IPO Strategy and Vision for Global Expansion

Xcell Therapeutics2024-10-01

Whanin Pharm Acquires 30% Stake in Microbiome Company Bifido

Whanin Pharm announced on the 30th that it has acquired 2,454,000 shares (30% stake) of microbiome company Bifido, gaining management control through a stock purchase agreement with Amicogen. Bifido, founded in 1999, specializes in probiotics and microbiome-based therapeutics, focusing on autoimmune disease treatments. It was the first microbiome company in South Korea to be listed on the KOSDAQ in 2018 under the tech-special listing system. Bifido has also achieved U.S. FDA certification for...

Whanin Pharmaceutical2024-10-01

Voronoi Withdraws IND Application for Lung Cancer Treatment VRN110755 from FDA

VORONOI2024-10-01

Vigencell Announces Completion of Cohort 2 for AML Treatment and Launch of Final Cohort in Phase 1 Trial

ViGENCELL2024-10-01

Ubix Therapeutics Signs Licensing Deal with Yuhan for Prostate Cancer Drug Candidate UBX-103

Ubix Therapeurics2024-10-01

Tego Science Initiates Phase 1 Clinical Trial for Allogeneic Cell Therapy for Wrinkle Improvement

TEGO SCIENCE2024-10-01

ST Pharm Presents Phase 1 Results of Basroparib at ESMO

ST Pharm2024-10-01

Shinpoong Pharmaceutical Prepares for Major R&D Investment with Phase 3 Stroke Treatment Trial

Shinpoong Pharmaceutical2024-10-01